My Patient Solutions
My Patient Solutions is a tool designed to help you enter and manage your patient cases with Genentech Access Solutions. Our easy-to-use online database tool offers you:
- Rapid access to all patient case files for single and multi-office practices
- Online completion, submission, printing and saving of the Statement of Medical Necessity (SMN) form
- Easy enrollment for new cases, with your practice information automatically populated
- Email and online alerts for your open cases
- Notifications about the latest news and developments from Genentech Access Solutions
- Quick links to the forms you need most often
Note: Register to use My Patient Solutions to obtain your unique User Name and Password before accessing the tool.
How My Patient Solutions Works
Once you have logged in, you can take the following actions in My Patient Solutions:
- Find, sort and select a patient's open case record to view status and benefits investigation results.
- Find, sort and select any closed patient case in the database.
- Download and print any required forms for patient enrollment.
- Enroll new patients for your practice online:
- Your practice information is automatically populated in the SMN by My Patient Solutions
- If the patient is already in our database, the demographic information is automatically populated by My Patient Solutions
- To enroll a new patient, you need the patient's contact and demographic information, insurance information, clinician information, medical history, prescribed therapy, indication and ICD-9 code(s)
- Update information and quickly re-enroll existing patients.
- View online alerts related to your patients' cases.
- Sign up for email alerts related to your patients' cases.
- See the latest news and updates from Genentech Access Solutions.
To start using My Patient Solutions now, please click on the log-in button in the upper right-hand corner of this screen. After you reach the My Patient Solutions log-in screen, you can click "Register Now" to request an account.
Herceptin (trastuzumab) Indications and Important Safety Information
Who is Herceptin for?
Herceptin is approved for the adjuvant treatment of HER2-overexpressing, node-positive or node-negative (ER/PR-negative or with one high-risk feature)* breast cancer. Herceptin can be used several different ways:
- As part of a treatment regimen including doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
- With docetaxel and carboplatin
- As a single agent following multi-modality anthracycline-based therapy
Herceptin in combination with paclitaxel is approved for the first-line treatment of HER2-overexpressing metastatic breast cancer. Herceptin as a single agent is approved for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.
*High-risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3.
What important safety information should I know about Herceptin?
Herceptin treatment can result in heart problems, including those without symptoms (reduced heart function) and those with symptoms (congestive heart failure). The risk and seriousness of these heart problems were highest in people who received both Herceptin and a certain type of chemotherapy (anthracycline). Your doctor will stop or strongly consider stopping Herceptin if you have a significant drop in your heart function.
You should be monitored for decreased heart function before your first dose of Herceptin, and frequently during the time you are receiving Herceptin and after your last dose of Herceptin. If you must permanently or temporarily stop Herceptin due to heart problems, you should be monitored more frequently. In one study with Herceptin and certain types of chemotherapy, an inadequate blood supply to the heart occurred.
Some patients have had serious infusion reactions and lung problems; fatal infusion reactions have been reported. In most cases, these reactions occurred during or within 24 hours of receiving Herceptin. Your Herceptin infusion should be temporarily stopped if you have shortness of breath or very low blood pressure. Your doctor will monitor you until these symptoms go away. If you have a severe allergic reaction, swelling, lung problems, inflammation of the lung, or severe shortness of breath, your doctor may need to completely stop your Herceptin treatment.
Worsening of low white blood cell counts associated with chemotherapy has also occurred.
Herceptin can cause low amniotic fluid levels and harm to the fetus when taken by a pregnant woman.
The most common side effects associated with Herceptin were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, shortness of breath, rash, low white and red blood cells, and muscle pain.
Because everyone is different, it is not possible to predict what side effects any one person will have. If you have questions or concerns about side effects, talk to your doctor.
Please see the Herceptin full Prescribing Information including Boxed WARNINGS and additional important safety information.
Herceptin® is a registered trademark and the Access Solutions logo and the Access Solutions Treatment made possible logo are trademarks of Genentech USA, Inc.
